BioAffinity Technologies Inc (NASDAQ: BIAF)’s stock price has plunge by 3.64relation to previous closing price of 0.29. Nevertheless, the company has seen a 8.39% surge in its stock price over the last five trading sessions. businesswire.com reported 2025-06-11 that SAN ANTONIO–(BUSINESS WIRE)– #ALA–bioAffinity CEO Maria Zannes joins the American Lung Association in Texas’ Leadership Board of to advance prevention and treatment of lung disease.
Is It Worth Investing in BioAffinity Technologies Inc (NASDAQ: BIAF) Right Now?
The 36-month beta value for BIAF is at 2.56. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for BIAF is 20.25M, and currently, shorts hold a 7.94% of that float. The average trading volume for BIAF on June 13, 2025 was 12.23M shares.
BIAF’s Market Performance
The stock of BioAffinity Technologies Inc (BIAF) has seen a 8.39% increase in the past week, with a 41.86% rise in the past month, and a -13.94% fall in the past quarter. The volatility ratio for the week is 2.36%, and the volatility levels for the past 30 days are at 12.89% for BIAF. The simple moving average for the last 20 days is 8.13% for BIAF stock, with a simple moving average of -67.24% for the last 200 days.
BIAF Trading at -22.13% from the 50-Day Moving Average
After a stumble in the market that brought BIAF to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.80% of loss for the given period.
Stock Fundamentals for BIAF
Current profitability levels for the company are sitting at:
- -1.09 for the present operating margin
- 0.34 for the gross margin
The net margin for BioAffinity Technologies Inc stands at -1.11. The total capital return value is set at -4.52. Equity return is now at value -290.85, with -143.25 for asset returns.
Based on BioAffinity Technologies Inc (BIAF), the company’s capital structure generated 0.48 points at debt to capital in total, while cash flow to debt ratio is standing at -4.93. The debt to equity ratio resting at 0.92. The interest coverage ratio of the stock is -114.15.
Currently, EBITDA for the company is -8.33 million with net debt to EBITDA at -0.1. When we switch over and look at the enterprise to sales, we see a ratio of 1.09. The receivables turnover for the company is 9.14for trailing twelve months and the total asset turnover is 1.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.55.
Conclusion
In conclusion, BioAffinity Technologies Inc (BIAF) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
